The University of Chicago Header Logo

Olwen Hahn

Concepts (218)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antineoplastic Combined Chemotherapy Protocols
22
2025
2666
1.290
Why?
Breast Neoplasms
21
2025
3303
1.280
Why?
Pyridines
9
2024
317
1.090
Why?
Triple Negative Breast Neoplasms
6
2025
218
0.880
Why?
Antineoplastic Agents
9
2024
2386
0.770
Why?
Kidney Neoplasms
7
2019
556
0.750
Why?
Carcinoma, Renal Cell
5
2019
384
0.570
Why?
Neoadjuvant Therapy
8
2024
477
0.540
Why?
Capecitabine
4
2024
103
0.540
Why?
Benzenesulfonates
2
2008
49
0.520
Why?
Chemotherapy, Adjuvant
7
2024
527
0.400
Why?
Watchful Waiting
3
2024
77
0.390
Why?
Enzyme Inhibitors
2
2007
641
0.390
Why?
Neoplasm Staging
13
2025
2087
0.380
Why?
Carcinoma, Small Cell
2
2017
116
0.370
Why?
Comparative Effectiveness Research
1
2012
62
0.350
Why?
Prostatic Neoplasms
5
2022
1846
0.350
Why?
Middle Aged
35
2025
29642
0.350
Why?
Aged
31
2025
21986
0.350
Why?
Lung Neoplasms
5
2018
2474
0.350
Why?
Urologic Neoplasms
2
2024
82
0.350
Why?
Protein Kinase Inhibitors
3
2024
642
0.350
Why?
Receptors, Estrogen
4
2024
431
0.340
Why?
Neoplasm Recurrence, Local
6
2025
1538
0.330
Why?
Antimetabolites, Antineoplastic
2
2024
246
0.330
Why?
Bevacizumab
8
2022
255
0.320
Why?
Aged, 80 and over
18
2024
7461
0.320
Why?
Students, Medical
3
2023
450
0.310
Why?
Receptors, Progesterone
3
2024
208
0.310
Why?
Neoplasms
6
2023
3382
0.300
Why?
Medical Oncology
3
2019
426
0.300
Why?
Radiosurgery
3
2021
352
0.290
Why?
Randomized Controlled Trials as Topic
2
2016
995
0.290
Why?
Humans
53
2025
98799
0.290
Why?
Anilides
3
2019
50
0.290
Why?
Female
38
2025
51997
0.280
Why?
Carcinoma, Non-Small-Cell Lung
3
2018
1177
0.270
Why?
Adult
26
2025
29698
0.270
Why?
Prostatectomy
2
2021
491
0.250
Why?
Bone Neoplasms
2
2019
316
0.250
Why?
Receptors, Vascular Endothelial Growth Factor
1
2006
58
0.240
Why?
Piperazines
3
2024
308
0.230
Why?
Protein-Tyrosine Kinases
1
2007
305
0.230
Why?
Pyrroles
2
2017
166
0.230
Why?
Weight Reduction Programs
1
2025
14
0.230
Why?
Disease-Free Survival
7
2024
1196
0.220
Why?
Education, Medical, Undergraduate
2
2019
191
0.220
Why?
Neutropenia
3
2021
211
0.220
Why?
Cyclin-Dependent Kinase 6
1
2024
21
0.220
Why?
Indoles
2
2017
340
0.210
Why?
Cyclin-Dependent Kinase 4
1
2024
37
0.210
Why?
Nitriles
3
2024
172
0.210
Why?
Trastuzumab
2
2021
98
0.200
Why?
Creatinine
1
2024
315
0.200
Why?
Weight Loss
1
2025
247
0.200
Why?
Aspirin
1
2024
168
0.190
Why?
Carcinoma, Transitional Cell
1
2024
158
0.190
Why?
Urinary Bladder Neoplasms
2
2024
403
0.190
Why?
Neoplasm Invasiveness
1
2024
583
0.180
Why?
Androgen Antagonists
2
2021
157
0.180
Why?
Vegetables
2
2020
50
0.180
Why?
Treatment Outcome
11
2025
9806
0.180
Why?
Interdisciplinary Studies
2
2019
19
0.180
Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2024
255
0.180
Why?
ErbB Receptors
1
2005
517
0.180
Why?
Schools, Medical
2
2023
137
0.180
Why?
Carboplatin
5
2025
331
0.170
Why?
Paclitaxel
5
2025
484
0.170
Why?
Antineoplastic Agents, Immunological
1
2024
238
0.170
Why?
Oxazoles
1
2021
14
0.170
Why?
Prostatic Neoplasms, Castration-Resistant
1
2023
121
0.170
Why?
Double-Blind Method
5
2024
1793
0.170
Why?
Clinical Competence
2
2018
873
0.170
Why?
Antibodies, Monoclonal, Humanized
3
2024
1105
0.160
Why?
Postmenopause
2
2024
109
0.160
Why?
Antineoplastic Agents, Hormonal
1
2021
161
0.160
Why?
Oncologists
1
2021
43
0.160
Why?
Triazoles
2
2024
118
0.160
Why?
Male
21
2024
47475
0.160
Why?
Quinazolines
1
2021
222
0.150
Why?
Leukemia
1
2022
310
0.150
Why?
Testosterone
1
2021
266
0.150
Why?
Drug-Related Side Effects and Adverse Reactions
2
2020
220
0.150
Why?
Neoplasm Metastasis
4
2016
1102
0.140
Why?
Angiogenesis Inhibitors
2
2021
281
0.140
Why?
Ovarian Neoplasms
1
2025
829
0.140
Why?
Soft Tissue Neoplasms
1
2019
127
0.140
Why?
Palliative Medicine
1
2018
11
0.140
Why?
Age Factors
1
2023
1976
0.140
Why?
Diet
2
2022
472
0.140
Why?
Obesity
1
2025
1079
0.140
Why?
Survival Analysis
4
2021
1530
0.130
Why?
Counseling
1
2020
191
0.130
Why?
Niacinamide
2
2008
105
0.130
Why?
Prospective Studies
5
2023
4837
0.130
Why?
Disease Progression
5
2021
1621
0.130
Why?
Phenylurea Compounds
2
2008
112
0.130
Why?
Cyclooxygenase 2
1
2017
101
0.120
Why?
Health Services Misuse
1
2016
20
0.120
Why?
Antibodies, Monoclonal
2
2021
1422
0.120
Why?
Curriculum
2
2019
643
0.120
Why?
Survival Rate
5
2019
2057
0.120
Why?
Patient-Centered Care
1
2019
233
0.120
Why?
Magnetic Resonance Imaging
1
2008
3622
0.120
Why?
Biomarkers, Tumor
2
2020
1786
0.120
Why?
Prognosis
5
2023
4139
0.120
Why?
Quality of Life
5
2025
1904
0.110
Why?
Follow-Up Studies
5
2024
4049
0.110
Why?
Deoxycytidine
3
2025
218
0.110
Why?
Needs Assessment
1
2016
174
0.110
Why?
Mifepristone
2
2025
59
0.110
Why?
Education, Medical, Graduate
1
2018
455
0.100
Why?
Area Under Curve
2
2018
341
0.100
Why?
Pediatrics
1
2018
422
0.100
Why?
Molecular Targeted Therapy
2
2016
331
0.090
Why?
Adenocarcinoma
1
2020
1215
0.090
Why?
Kaplan-Meier Estimate
3
2024
909
0.090
Why?
Telephone
2
2025
43
0.090
Why?
Intensive Care Units
1
2016
476
0.090
Why?
Young Adult
5
2024
7598
0.090
Why?
Proportional Hazards Models
2
2018
925
0.090
Why?
Maximum Tolerated Dose
2
2025
265
0.080
Why?
Intention to Treat Analysis
2
2024
82
0.080
Why?
Sirolimus
1
2012
181
0.080
Why?
Hospitalization
1
2016
993
0.080
Why?
Fatigue
3
2017
187
0.080
Why?
Retrospective Studies
5
2024
11104
0.080
Why?
Clinical Trials as Topic
2
2021
1128
0.070
Why?
Combined Modality Therapy
2
2023
1754
0.070
Why?
Internship and Residency
1
2018
1132
0.070
Why?
Placebos
1
2008
210
0.070
Why?
Gadolinium DTPA
1
2008
239
0.070
Why?
Oncogenes
1
2007
102
0.060
Why?
Dose-Response Relationship, Drug
2
2024
1949
0.060
Why?
Prostate-Specific Antigen
2
2020
356
0.060
Why?
Pandemics
2
2023
923
0.060
Why?
Cell Cycle
1
2007
519
0.060
Why?
Pilot Projects
2
2019
978
0.050
Why?
Thrombocytopenia
2
2017
194
0.050
Why?
Albumins
1
2025
126
0.050
Why?
Aminopyridines
1
2024
54
0.050
Why?
Purines
1
2024
97
0.050
Why?
Drug Administration Schedule
2
2016
837
0.050
Why?
Ki-67 Antigen
1
2024
70
0.050
Why?
Benzimidazoles
1
2024
120
0.050
Why?
Canada
1
2024
210
0.050
Why?
Contrast Media
1
2008
1014
0.050
Why?
Cohort Studies
2
2023
3242
0.050
Why?
Receptors, Glucocorticoid
1
2025
145
0.050
Why?
Abiraterone Acetate
1
2023
14
0.050
Why?
Risk Factors
3
2020
6295
0.050
Why?
United States
3
2024
8387
0.050
Why?
Androstenes
1
2023
42
0.050
Why?
Phenylthiohydantoin
1
2023
58
0.050
Why?
Administration, Oral
1
2024
677
0.050
Why?
Prednisone
1
2023
252
0.050
Why?
Cancer Survivors
1
2024
110
0.040
Why?
B7-H1 Antigen
1
2024
333
0.040
Why?
Mastectomy, Segmental
1
2023
119
0.040
Why?
Benzamides
1
2023
260
0.040
Why?
Time Factors
2
2021
5586
0.040
Why?
Radiotherapy, Adjuvant
1
2023
325
0.040
Why?
Body Mass Index
1
2025
869
0.040
Why?
Ipilimumab
1
2021
69
0.040
Why?
Radiation Oncologists
1
2021
15
0.040
Why?
Surveys and Questionnaires
2
2021
3058
0.040
Why?
Breast
1
2023
317
0.040
Why?
Patient Care Planning
1
2021
92
0.040
Why?
Neoplasm, Residual
1
2022
205
0.040
Why?
Ferredoxin-NADP Reductase
1
2020
15
0.040
Why?
Methylenetetrahydrofolate Reductase (NADPH2)
1
2020
28
0.040
Why?
Perception
1
2021
190
0.040
Why?
Hypertension
2
2017
791
0.040
Why?
Learning
1
2023
313
0.040
Why?
Mastectomy
1
2021
277
0.040
Why?
Evaluation Studies as Topic
1
2019
244
0.040
Why?
Neovascularization, Pathologic
1
2021
356
0.040
Why?
Cisplatin
1
2021
578
0.040
Why?
Health Personnel
1
2021
259
0.030
Why?
Training Support
1
2018
23
0.030
Why?
Tamoxifen
1
2019
177
0.030
Why?
Prostate
1
2022
434
0.030
Why?
Consolidation Chemotherapy
1
2018
23
0.030
Why?
Radiation Pneumonitis
1
2018
23
0.030
Why?
Interprofessional Relations
1
2019
122
0.030
Why?
Hemoptysis
1
2018
27
0.030
Why?
Cyclooxygenase 2 Inhibitors
1
2017
36
0.030
Why?
Celecoxib
1
2017
34
0.030
Why?
Dinoprostone
1
2017
79
0.030
Why?
Pemetrexed
1
2017
76
0.030
Why?
Platinum Compounds
1
2017
29
0.030
Why?
Mucositis
1
2017
18
0.030
Why?
Educational Measurement
1
2019
243
0.030
Why?
Drug Eruptions
1
2017
35
0.030
Why?
Germ-Line Mutation
1
2020
404
0.030
Why?
Program Evaluation
1
2018
349
0.030
Why?
Signal Transduction
1
2007
3642
0.030
Why?
Maintenance Chemotherapy
1
2017
96
0.030
Why?
Odds Ratio
1
2018
728
0.030
Why?
Selection Bias
1
2016
40
0.030
Why?
Anemia
1
2017
135
0.030
Why?
Standard of Care
1
2016
71
0.030
Why?
Genotype
1
2020
1895
0.030
Why?
Terminal Care
1
2016
147
0.030
Why?
Transcriptome
1
2020
828
0.030
Why?
Biomarkers
1
2021
2026
0.030
Why?
Cyclophosphamide
1
2014
285
0.020
Why?
Doxorubicin
1
2014
285
0.020
Why?
Incidence
1
2018
1798
0.020
Why?
Biopsy
1
2017
1226
0.020
Why?
Risk Assessment
1
2020
2604
0.020
Why?
Remission Induction
1
2014
764
0.020
Why?
Polymorphism, Single Nucleotide
1
2020
2577
0.020
Why?
MicroRNAs
1
2016
609
0.020
Why?
Fluorouracil
1
2011
543
0.020
Why?
Child
1
2018
7771
0.010
Why?
Chicago
1
2011
1520
0.010
Why?
Mutation
1
2012
4443
0.010
Why?
Hahn's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (218)
Explore
_
Co-Authors (55)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_